Par Pharmaceutical Companies (PRX)
Par Pharmaceutical Companies Interest Expense: 3.094M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PRX Interest Expense Rankings
| Overall | 31st percentile | 3196 of 4657 |
| Sector | 19th percentile | 423 of 525 in Healthcare |
| Industry | 21st percentile | 11 of 14 in Drugs - Generic |
PRX Interest Expense Range, Past 5 Years
| Minimum | 0.15M | Mar 2011 |
| Maximum | 8.645M | Dec 2007 |
| Average | 2.105M |
About Interest Expense
When companies borrow money to expand or maintain their business operations, they must pay interest on the money that they borrow. The interest expense is the annual accrued amount of interest that the company paid (or sometimes will have to pay) to its creditors.
YCharts includes both operating interest expense and non-operating interest expense in our numbers.
Learn More
You may also be interested in these PRX related companies
PRX News
RT @TraderRadar $AAPL $NFLX $PRX Keep these on your radar for higher prices next week// $NFLX based on what evidence??
about a day ago by lipong23
about a day ago by lipong23
$AAPL $NFLX $PRX Keep these on your radar for higher prices next week
about a day ago by TraderRadar
about a day ago by TraderRadar
@TraderRadar Like $PRX - should keep moving after pull back to $39 area
about a day ago by OMillionaires
about a day ago by OMillionaires
UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Comments From Conference Call
May 09, 12:21PM Street Insider
May 09, 12:21PM Street Insider
Listen to $PRX Q1 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3iVK
about 18 days ago by earningscast
about 18 days ago by earningscast
Also sold my $HMSY on weakness. Picked up shares of $PRX Friday. Any thoughts?
about 35 days ago by robertfreedland
about 35 days ago by robertfreedland
Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Healthy Deal with Handa
Apr 20, 9:46AM Street Insider
Apr 20, 9:46AM Street Insider
Par Pharmaceutical Acquires Rights to Market and Distribute Generic Dexilant® in the U.S.
Apr 19, 3:05PM Benzinga
Apr 19, 3:05PM Benzinga
Par Pharmaceutical Companies to Report First Quarter 2012 Results on May 8, 2012
Apr 09, 9:00AM PR Newswire
Apr 09, 9:00AM PR Newswire
$PRX is 5.0% up since open on unusual high volume and 5.5% up since close.
about 51 days ago by TradeBot
about 51 days ago by TradeBot
$WCG $CL $SJM $PRX Hit 52-Week Highs http://stks.co/39sz My story via @TheStreet #52WeekHigh
about 57 days ago by azendrian
about 57 days ago by azendrian
$PRX filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/39RA
about 57 days ago by MarketBrief
about 57 days ago by MarketBrief
Horizon Pharma (HZNP) Files Patent Infringement Suit Against Par Pharma (PRX) Over DUEXIS Tabs
Mar 28, 4:30PM Street Insider
Mar 28, 4:30PM Street Insider
$PRX forms bullish "Symmetrical Continuation Triangle" chart pattern. http://stks.co/33Pn
about 64 days ago by RecogniaEvents
about 64 days ago by RecogniaEvents
Impressive development programs, partnerships and product launch prep make IntelGenX look like a solid bet at these prices
Mar 23, 8:34AM Thomson Reuters ONE
Mar 23, 8:34AM Thomson Reuters ONE
$PRX forms bearish "Triple Top" chart pattern. http://stks.co/2epQ
about 85 days ago by RecogniaEvents
about 85 days ago by RecogniaEvents
Listen to $PRX Q4 2011 earnings call - live at 09:00 AM, ondemand after - http://stks.co/2af5
about 88 days ago by earningscast
about 88 days ago by earningscast
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PRX | 40.88 | +1.34 | +3.39% | 1.495B |
| PRU | 47.20 | -0.13 | -0.27% | 22.17B |
| PRST | 0.56 | +0.01 | +1.82% | 20.93M |
| PRO | 15.83 | +0.04 | +0.25% | 429.15M |
| PRLS | 3.78 | +0.00 | +0.00% | 13.38M |
| PRGO | 103.00 | +0.08 | +0.08% | 9.610B |
| PRGN | 0.58 | +0.00 | +0.83% | 34.72M |
| PRFT | 11.57 | +0.10 | +0.87% | 361.79M |
| PRF | 56.28 | -0.01 | -0.02% | |
| PRE | 72.31 | +0.30 | +0.42% | 4.728B |
